|
|
 Previous Article | Table of Contents | Next Article 
Characterization of endogenous cytokine concentrations after high-dose
chemotherapy with autologous bone marrow support
J Rabinowitz, WP Petros, AR Stuart and WP Peters
Department of Medicine, Duke University Medical Center, Durham, NC 27710.
Endogenous cytokines are thought to mediate numerous biologic processes and
may account for some adverse effects experienced following the
administration of recombinant proteins. This study describes the pattern of
endogenous cytokine exposure following high-dose chemotherapy. Blood
concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha
(TNF-alpha), macrophage colony-stimulating factor (M-CSF), and
erythropoietin (EPO) were measured by enzyme-linked immunosorbent assay
(ELISA) methods in 68 patients receiving the same ablative chemotherapy
regimen (cyclophosphamide, cisplatin, carmustine). Patients were grouped
according to cellular support (autologous bone marrow [BM] CSF-primed
peripheral blood progenitor cells [PBPCs]) and prescribed growth factor
(recombinant human granulocyte or granulocyte-macrophage colony-stimulating
factor [rHuG- CSF or rHuGM-CSF]). Leukocyte reconstitution was most
accelerated in the groups treated with PBPCs and rHuG-CSF. IL-6, M-CSF, and
TNF-alpha concentrations were higher in the groups treated with rHuGM-CSF
and without PBPCs. Maximal endogenous cytokine concentrations occurred
approximately 12 days after BM reinfusion. High concentrations of EPO
occurred in patients experiencing significant hypotension despite routine
transfusions for hematocrit < 42%. High M-CSF and IL-6 levels were
associated with increased platelet transfusion requirements. Concentrations
of all four cytokines were significantly higher in patients experiencing
renal or hepatic toxicity, with elevations occurring in a predictable
sequence and M-CSF elevations occurring first. This report shows that
endogenous cytokine concentrations may be influenced by either cellular or
CSF support and are associated with differences in platelet reconstitution
and organ toxicity.
Volume 81,
Issue 9,
pp. 2452-2459,
05/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Voog, J. Bienvenu, K. Warzocha, I. Moullet, C. Dumontet, C. Thieblemont, G. Monneret, M.-C. Gutowski, B. Coiffier, and G. Salles
Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System
J. Clin. Oncol.,
January 14, 2000;
18(2):
325 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Folz and M. A. Elkordy
Coronavirus Pneumonia Following Autologous Bone Marrow Transplantation for Breast Cancer
Chest,
March 1, 1999;
115(3):
901 - 905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Gupta, B. R. Blazar, K. Gupta, and C. M. Verfaillie
Human CD34+ Bone Marrow Cells Regulate Stromal Production of Interleukin-6 and Granulocyte Colony-Stimulating Factor and Increase the Colony-Stimulating Activity of Stroma
Blood,
May 15, 1998;
91(10):
3724 - 3733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Liu, J. Poursine-Laurent, and D. C. Link
The Granulocyte Colony-Stimulating Factor Receptor Is Required for the Mobilization of Murine Hematopoietic Progenitors Into Peripheral Blood by Cyclophosphamide or Interleukin-8 But Not Flt-3 Ligand
Blood,
October 1, 1997;
90(7):
2522 - 2528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nagler, A. Ackerstein, R. Or, E. Naparstek, and S. Slavin
Immunotherapy With Recombinant Human Interleukin-2 and Recombinant Interferon-alpha in Lymphoma Patients Postautologous Marrow or Stem Cell Transplantation
Blood,
June 1, 1997;
89(11):
3951 - 3959.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Testa, R. Martucci, G. Scambia, P. Benedetti Panici, S. Mancuso, A. Camagna, G. Mastroberardino, L. Pierelli, G. Menichella, and C. Peschle
Autologous Stem Cell Transplantation: Exogenous Granulocyte Colony-Stimulating Factor or Granulocyte-Macrophage Colony-Stimulating Factor Modulate the Endogenous Cytokine Levels
Blood,
April 1, 1997;
89(7):
2615 - 2617.
[Full Text]
[PDF]
|
|
|
|
|
